Back to Authors

Zhao, Jimmy

Mayo Clinic

Memorial Sloan Kettering Cancer Center

Citations 1

MYC pathway reprogramming through a TIP60 coactivator switch in neuroendocrine lineage transition in prostate cancer
Sun, Zhen , Zhao, Jimmy, Khan, Zahra, Ismail, Wazim, Han, Teng, Nandakumar, Subhiksha, Young, Serina, Lange, Matthew , Cheng, Pan, Koche, Richard, Schultz, Nikolaus, Sawyers, Charles, Gaspar-Maia, Alexandre , Sawyers, Charles L. , Han, Teng , Nandakumar, Subhiksha , Koche, Richard P , Schultz, Nikolaus D. , Gaspar‐Maia, Alexandre

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.05.723058 Get It

Abstract Prostate adenocarcinomas (PRAD) can acquire resistance to androgen receptor signaling inhibitors through lineage transition to a cell state known as neuroendocrine prostate cancer (NEPC). Using a panel of isogenic PRAD and NEPC mouse tumoroids, we show that NEPC cells acquire new transcription factor (TF) dependencies that function in a previously undefined network. Through selective perturbation of each TF, we identify ASCL1 as a key regulator of NE lineage fate whereas MYCL functions downstream to drive NEPC growth/survival by recruitment of the TIP60/KAT5 acetyltransferase. Interestingly, while dependencies on specific TF family paralogs can vary across NEPC models, all show markedly enhanced dependency on TIP60. Moreover, the H2A.Z-acetyltransferase activity of the TIP60 complex (TIP60-C) is required for NEPC as well as the acetyl-reader BRD8, which is newly incorporated as a TIP60-C subunit with the NEPC transition. Targeted degradation studies in isogenic tumoroids reveal increased dependence on MYCL in NEPC relative to its paralog MYC in PRAD. In addition to a paralog switch (MYC to MYCL), the MYC pathway-addicted NE state is accompanied by a chaperone switch (from TIP60-C to SRCAP) for H2A.Z histone exchange and a coactivator switch (to TIP60) for MYC target gene expression. The NE-specific coupling of MYCL with TIP60 reveals a previously unappreciated opportunity to target MYC-driven NE diseases through pharmacological inhibition of TIP60.